Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 1245a (MIR1245A)
- Target
- MIR1245A
- Molecular classification
- MicroRNA, Non-coding RNA, Regulatory RNA
01
Overview
MicroRNA 1245a (MIR1245A) is a small, non-coding RNA molecule, part of the regulatory microRNA family. It specifically functions by binding to complementary sequences in the 3' untranslated regions (UTRs) of target messenger RNAs, leading to their degradation or inhibiting their translation. MIR1245A is upregulated in colon adenocarcinoma and promotes malignant behaviors such as cellular proliferation and invasion by targeting tumor suppressor genes including BRCA2. Its modulation is associated with poor prognosis in certain cancers, suggesting its utility as a biomarker and a potential therapeutic target. Chemically modified antisense oligonucleotides that inhibit MIR1245A have been developed for research and possible clinical use. As with other miRNAs, broad involvement in gene regulatory networks creates substantial therapeutic challenges, particularly regarding specificity and potential side effects.
- Other names
- hsa-miR-1245ahsa-mir-1245amiR-1245aMIR1245microRNA 1245MIRN1245hsa-mir-1245mir-1245a
02
Mechanism of action
Antisense inhibition of mature miRNA function (by inhibitor oligonucleotides)
03
Biological functions
Gene expression regulationPost-transcriptional silencing via mRNA interferenceCell proliferationCell invasionTumor progression
04
Disease associations
Cancer (promotes proliferation and invasion in colon cancer, evidence in breast and lung cancers)Neurodegenerative disease (potential regulatory roles suggested; see sarcopenia/neurodegeneration context)
05
Safety considerations
Broad gene network modulation (typical of microRNA-based interventions, can impact numerous mRNAs and cellular pathways; potential off-target effects, risk of unwanted cellular/tissue responses)
06
Interacting drugs
hsa-miR-1245a inhibitor (chemically modified oligonucleotides targeting miR-1245a)
07
Biomarkers
Expression level of miR-1245a (proposed for colon adenocarcinoma progression and prognosis)
Beyond the preview
Go deeper on MicroRNA 1245a (MIR1245A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MicroRNA 1245a (MIR1245A).